Vaginal News and Research

RSS

HRT reduces risk of breast cancer in women with BRCA mutations after ovary removal

Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.

4 Jun 2011

Loss of elasticity and protein breakdown cause pelvic organ prolapse

A gynecologist and a molecular biologist at UT Southwestern Medical Center have collaborated to show for the first time that pelvic organ prolapse - a condition in which the uterus, bladder or vagina protrude from the body - is caused by a combination of a loss of elasticity and a breakdown of proteins in the vaginal wall.

24 May 2011

Australians discover treatment for very common female infection

Starpharma Holdings Limited has announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

22 May 2011

Humanized BLT mice help prevent HIV/AIDS transmission

The more than 2.7 million new HIV infections recorded per year leave little doubt that the HIV/AIDS epidemic continues to spread globally. That's why there's the need for safe, inexpensive and effective drugs to successfully block HIV transmission.

19 May 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

AMS signs research grant contract for six sites to evaluate vaginal prolapse repair techniques

American Medical Systems a leading provider of world-class devices and therapies for male and female pelvic health, announced today the signing of a research grant contract for six sites to evaluate anatomical, functional and safety outcomes of two different treatments for vaginal prolapse, Anterior Colporrhaphy, a technique which uses traditional suture plication, versus the Elevate Anterior and Apical Prolapse Repair System.

13 May 2011

Longer looks: Conservatives vs. liberals on Medicare - who's winning?

What you really need to know is that Tuesday was a great day in court for supporters of the Care Act and a very tough one for its opponents. That dynamic could easily change within the next six weeks or so when the 11th Circuit, the 6th Circuit, and the 3rd Circuit also hold their oral arguments on Care Act appeals. Either way, we are one step closer to the end of all of this, and you can bet that the justices were paying attention up the road a bit from Richmond.

13 May 2011

Mesh surgery more effective for patients with pelvic organ prolapse

A Nordic multicentre study, headed by researchers from Karolinska Institutet in Sweden, shows that pelvic organ prolapse surgery using synthetic mesh can be more effective than traditional surgery.

12 May 2011

Starpharma inks licence agreement in Japan with Okamoto for VivaGel-coated condoms

Starpharma Holdings Limited today announced that it has signed a licence agreement with Okamoto Industries Inc in relation to the VivaGel(r)-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

10 May 2011

SRS Medical announces pelvic health program for women

SRS Medical today announced the formation of Restore Continence™, a women's pelvic health program based on the use of a comprehensive suite of medical devices for diagnosing and treating urinary incontinence.

3 May 2011

Simbionix to exhibit new training simulator for pelvic floor repair at ACOG

Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is pleased to announce its new training simulator for pelvic floor repair, to be exhibited for the first time at the ACOG 59th Annual Clinical Meeting in Washington, DC, April 30- May 4, 2011.

3 May 2011

C-section deliveries have increased by 72%, episiotomy and forceps use have declined

Use of episiotomy, a surgical incision to widen the vaginal area during childbirth, fell by 60 percent between 1997 and 2008, according to the latest News and Numbers by the Agency for Healthcare Research and Quality.

29 Apr 2011

IL28B gene plays a key role in spontaneous HCV clearance in infants

New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.

28 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Fibulin-5 protein can help prevent pelvic organ prolapse development in women

Pelvic organ prolapse is a disabling condition that affects almost 50% of women over the age of 50. It occurs when the muscles and ligaments supporting a woman's pelvic organs weaken such that the pelvic organs slip out of place, often protruding into the vagina.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Gen-Probe receives FDA marketing clearance for APTIMA Trichomonas vaginalis assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.